Amicus Therapeutics Inc

Amicus Therapeutics — Corporate Update (September 2023)

11 slides from Amicus Therapeutics's corporate update, Sep 28, 2023

  1. Slide 1: U.S. Approval Call: Pombiliti + Opfolda

    U.S. Approval Call: Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) September 28, 2023

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to approval and commercialization plans for Pombiliti and Opfolda in the United States. The inclusion of forward-looking statements

  3. Slide 3: Executive Summary

    3 Executive Summary New treatment for adults living with late-onset Pompe disease 3 Late-onset Pompe disease is a rare and fatal genetic disease that is significantly underdiagnosed Pombiliti + Opfolda is a differentiated two-component therapy for adults who are not improving on their current therap

  4. Slide 4: Late-onset Pompe Disease (LOPD) Overview

    4 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Diagnosed at different stages of life, from childhood to adulthood Symptoms include progressive muscle weakness, particularly skeletal and respiratory muscles, that worsens over time Respiratory failure and loss

  5. Slide 5: An Innovative Approach to Pompe Disease

    5 Pombiliti + Opfolda: An Innovative Approach to Pompe Disease Our scientists created a uniquely glycosylated and highly phosphorylated ERT that enhances targeting to key affected muscles and is co-administered with an enzyme stabilizer & Pombiliti + Opfolda is a two-component therapy combining cipa

  6. Slide 6: U.S. Label Highlights

    6 U.S. Label Highlights Pombiliti + Opfolda approved in the United States & Pombiliti + Opfolda indicated for the treatment of adults with late-onset Pompe (LOPD) disease weighing ≥40 kg and who are not improving on their current enzyme replacement therapy & This indication is approved based on posi

  7. Slide 7: U.S. Opportunity

    7 Pombiliti + Opfolda U.S. Opportunity Alaska Hawaii Universally screened Not screened Pompe Disease Newborn Screening in 44 U.S. States2 & ~80% of the 800 treated patients in the U.S. are adults1 & Currently ~40 patients in the U.S. on Pombiliti + Opfolda through clinical trials are eligible for co

  8. Slide 8: Launch Activities

    8 Pombiliti + Opfolda Launch Activities Experienced and passionate rare disease commercial and medical organizations poised for second successful launch & Market mapping and account profiling completed & Sales team visiting top accounts in first 30 days & Promotional materials developed & Product la

  9. Slide 9: Pricing Promise

    9 Pricing Promise Pombiliti + Opfolda U.S. Pricing & Combined price of Pombiliti + Opfolda slightly below current treatments & Pricing PROMISE: Amicus will limit price increases to CPI-U (consumer price index) & Pledge for a Cure: Amicus pledges to reinvest a portion of our profits into R&D of new t

  10. Slide 10: 2023 Strategic Priorities

    2023 Strategic Priorities Double-digit Galafold® revenue growth of 14-18% at CER1 Secure FDA, EMA, and MHRA approvals for Pombiliti + Opfolda Initiate successful global launches of Pombiliti + Opfolda Advance best-in-class, next-generation Fabry and Pompe pipeline programs and capabilities Maintain

  11. Slide 11: Thank You

    Therapeutics Thank You

Amicus Therapeutics — Corporate Update (September 2023) on 6ix